MITRACLIP IN THE SETTING OF CARDIOGENIC SHOCK: BEYOND COAPT

James Deen  
*Cedars-Sinai Medical Center*, jdeen@med.wayne.edu

Tohar Lev  
*Cedars-Sinai Medical Center*, tohark@mail.tau.ac.il

Joseph Ebinger  
*Cedars-Sinai Medical Center*, joseph.ebinger@csmc.edu

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs

Part of the Medicine and Health Sciences Commons

Recommended Citation
Deen, James; Lev, Tohar; and Ebinger, Joseph, "MITRACLIP IN THE SETTING OF CARDIOGENIC SHOCK: BEYOND COAPT" (2020). Medical Student Research Symposium. 38.  
https://digitalcommons.wayne.edu/som_srs/38

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Title:
MITRACLIP IN THE SETTING OF CARDIOGENIC SHOCK: BEYOND COAPT

Authors:
Deen, James, MS., Lev, Tohar, BS., Ebinger, Joseph, MD.

Purpose of the study:
To assess the short- and long-term outcomes of patients undergoing MitraClip for severe MR in the setting of cardiogenic shock.

Methods:
This was a retrospective observational cohort study of patients who underwent MitraClip at a large academic institution between 2013 and 2019. Charts were reviewed to identify patients with pre-procedure cardiogenic shock if at least 1 of the following was present: 1) documentation of ongoing cardiogenic shock by a provider, 2) cardiac index <2.2 or 3) use of inotropes (Dobutamine, Milrinone or Dopamine) or vasopressors (Norepinephrine, Epinephrine or Vasopressin) within 24 hours of the procedure.

Results:
Out of 448 MitraClip patients, 29 (6.5%) were identified as having pre-procedure cardiogenic shock. Of those in cardiogenic shock prior to MitraClip, 26 (90%) were on inotropes and 16 (55%) were on vasopressors. This decreased to 22 (76%) and 15 (52%) post-procedure, respectively, though did not reach statistical significance (p=0.80). On pre-procedure echocardiography, MR severity was graded as severe or very severe in 21 (72.4%) of those with cardiogenic shock and 301 (71.8%) of those without shock. Of these patients, MR severity was reduced to moderate or less in 26 (89.7%) of those with shock and 400 (95.5%) of those without shock following the procedure (p=0.80).

Conclusion:
Use of MitraClip for the treatment of MR in the setting of cardiogenic shock is feasibility, with noted reductions in the severity of MR and inotropic requirements.

Key Words:
MitraClip, cardiogenic shock, mitral regurgitation, inotropes, vasopressors